From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Study
No. patients
Median OS (months)
HR
CA209-067 [1, 2]
n + i = 314
n = 316
n + i = NR
n = 36.93
HR 0.83
CA209-227 [4]
(OS PD-L1 > 1%)
n + i = 396
n = 396
n + i = 17.1
n = 15.7
HR 0.79
